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Computational methods can be applied in drug development for the identiﬁcation of novel lead can-
didates, but also for the prediction of pharmacokinetic properties and potential adverse effects, thereby
aiding to prioritize and identify the most promising compounds. In principle, several techniques are
available for this purpose, however, which one is the most suitable for a speciﬁc research objective still
requires further investigation. Within this study, the performance of several programs, representing
common virtual screening methods, was compared in a prospective manner. First, we selected top-
ranked virtual screening hits from the three methods pharmacophore modeling, shape-based
modeling, and docking. For comparison, these hits were then additionally predicted by external phar-
macophore- and 2D similarity-based bioactivity proﬁling tools. Subsequently, the biological activities of
the selected hits were assessed in vitro, which allowed for evaluating and comparing the prospective
performance of the applied tools. Although all methods performed well, considerable differences were
observed concerning hit rates, true positive and true negative hits, and hitlist composition. Our results
suggest that a rational selection of the applied method represents a powerful strategy to maximize the
success of a research project, tightly linked to its aims. We employed cyclooxygenase as application
example, however, the focus of this study lied on highlighting the differences in the virtual screening tool
performances and not in the identiﬁcation of novel COX-inhibitors.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
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In silico tools are nowadays well integrated in the drug devel-
opment process and are considered a complementary approach to
experimental methods. They have proved to successfully identify
ligandetarget interactions [1] and to enrich active compounds in
the libraries selected for biological testing [2]. Although they were
originally used for the prediction of novel disease-modulating
compounds for a speciﬁc target, additional strategies arise [1].
Besides classical lead-identiﬁcation, in silico tools can also be
deployed for the investigation of off-target interactions. These
additional interaction predictions can comprise basically all targets
for which sufﬁcient data, structural or ligand-based, is available for
model building. Via the parallel screening of multiple targets
against one compound, so-called bioactivity proﬁles can be
generated. They can help to predict adverse events as well asss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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identify the most promising drug candidates and to exclude com-
pounds with a bad risk proﬁle [7]. In principle, a lot of different
approaches can be used to address these issues. Among the most
commonly used in silico tools are docking and similarity-based
methods. Similarity-based methods rely upon the assumption
that similar molecules exert similar biological effects. Compounds
can be compared according to their 2D structure (2D similiarity-
based methods), or, in a 3D approach, according to their size and
shape (shape-based modeling) or their electrochemical features
(pharmacophore modeling). According to IUPAC, “a pharmaco-
phore is the ensemble of steric and electronic features that is
necessary to ensure the optimal supra-molecular interactions with
a speciﬁc biological target structure and to trigger (or to block) its
biological response” [8]. These features represent properties like
hydrogen bond donor (HBD)/acceptor (HBA) or hydrophobic (H)
parts of a molecule rather than speciﬁc functional groups. In
addition, a model can contain exclusion volumes (XVOLs) that
mimic the binding site and into which a molecule is not allowed to
protrude in order to avoid steric clashes with the target. Shape-
based methods, for example Rapid Overlay of Chemical Structures
(ROCS) [9,10], can be optimized by also including chemical infor-
mation in addition to shape characteristics [11]. The main prereq-
uisite for docking is 3D structural information about the target
derived from e.g. X-ray crystallography, NMR studies, or homology
modeling. Basically, docking comprises two steps. First, the ligand
is ﬁtted into the binding site, and second the “quality” of the
interaction pose is evaluated with scoring functions. The results can
then be ranked according to their scores with compounds more
likely to be active ranked at the top [12].
Within this study, we applied established virtual screening tools
based on all methods mentioned above in parallel and investigated
their performances in a prospective screening. In principle, multi-
ple virtual screening software tools are available for every method.
For our pharmacophore-based investigations, we selected the
program LigandScout [13]. In a recent comparative study of
pharmacophore-based virtual screening programs LigandScout
was within the best performing tools for all applied case studies
when it comes to early enrichment rates [14]. The software pro-
gram ROCS was employed for shape-based virtual screening. For
the docking studies, we used the program GOLD [15,16], because it
was shown to be among the best performing and most robust
programs in a comparison of docking tools [17]. Also a recent study
highlighted the good performance of GOLD, thereby approving our
choice [18].
For additional bioactivity proﬁling, but not for selecting test
compounds, we employed two 2D similarity-based (SEA [19] and
PASS [20]) and two external pharmacophore-based (PharmMapper
[6] and PharmaDB [21]) software tools. All these tools screen the
compound against a plethora of diverse targets and therefore
provide a whole in silico bioactivity spectrum rather than pre-
dictions against one single target.
All these methods have been applied successfully for the iden-
tiﬁcation of novel bioactive compounds [22e24], but which
method is the most suitable for a speciﬁc target class or research
questions still remains largely elusive. In addition, in a recent study,
we could observe substantial differences even between programs
that rely upon the same methodology. Both of the two applied
pharmacophore modeling software tools, LigandScout and Dis-
covery Studio [25], were able to identify novel bioactive com-
pounds, but there was no overlap in the retrieved hitlists [26]. We
therefore assumed that the differences in the performances may be
even more pronounced between programs based on different
methods such as shape-based screening and docking as applied in
this study.Several performance evaluations have been published recently
[10,21,27e31], which points out the arising interest in addressing
this question. However, in most cases different datasets and com-
binations of methods have been applied, thereby limiting a direct
comparison of the results. In addition, most of these studies are
retrospective, and the performance of the investigated methods
may differ in a prospective screening. Therefore, an exhaustive
prospective comparison of both ligand- and target-based methods
still needs to be performed. Tresadern et al. also included a pro-
spective part in their comparison, where they evaluated the per-
formance of Extended-connectivity ﬁngerprints (ECFP) 6, Ftrees,
Topomers, Cresset FieldScreen, and ROCS OpenEye Shape Tanimoto
(OEST), OpenEye ComboScore (OECS), and OpenEye electrostatics
in identifying ligands for the corticotropin releasing factor 1 re-
ceptor. However, the prospective aspect only comprised Topomers,
Cresset, OEST, and OECS. Pharmacophore modeling and docking
were missing in this study [28]. In 2010, Krüger and Evers retro-
spectively compared the enrichment factors of several docking
protocols, ROCS, Feature Trees, and Scitegic Functional Fingerprints
and investigated the hitlist complementarity. For their study, they
used four different targets, namely angiotensin-converting enzyme
(ACE), thrombin, human immunodeﬁciency virus 1 (HIV-1) prote-
ase, and cyclooxygenase (COX) 2 [30]. We also selected COX-2, in
addition to COX-1, for our studies, because a lot of biological data is
already available to theoretically set up the models. Although we
used both isoforms for the experiment, we have to clarify at the
beginning that we did not intend to investigate the mechanisms
underlying COX-selectivity. We employed COX only as application
example, the identiﬁcation of novel COX-inhibitors is therefore also
of subordinate importance. The aim of the study is the investigation
of the performances of several different software tools for the
identiﬁcation of inhibitors for classical enzymes and to determine
their advantages and limits. This study does not provide a quanti-
tative evaluation of the programs, but highlights the observed
differences resulting from the distinct virtual screening concepts.
For this purpose, we selected widely used, representative virtual
screening programs (LigandScout for pharmacophore modeling,
ROCS for shape-based modeling, and GOLD for docking) and
bioactivity proﬁling tools (SEA and PASS for 2D-similarity based
proﬁling and PharmaDB and PharmMapper for pharmacophore-
based proﬁling). They were applied independently for the predic-
tion of COX activity of selected virtual hits. The biological testing of
the hits allowed for a prospective evaluation of all applied tools and
their direct performance comparison.
2. Methods
2.1. Study design
Over the course of this study, several shape-based models as
well as a docking protocol were developed and theoretically vali-
dated. In addition, a previously reported collection of already
validated (theoretically and experimentally) COX pharmacophore
models created with LigandScout [26] was included in the study.
This served as a direct comparison of the performances of these
virtual screening tools and was intended also as a follow-up study
to the previously published comparison of the two
pharmacophore-based virtual screening tools Discovery Studio and
LigandScout [26]. In this study, we could observe quite substantial
differences in the performances of these two programs [26], and
assumed that the differences might be even more pronounced
when using methods underlying a different virtual screening
concept, such as shape-based modeling or docking. The best per-
forming pharmacophore and shape-based models as well as the
docking workﬂow were used for virtual screening of the in-house
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bruck. The activity of top-ranked hits was also predicted with
additional external in silico proﬁling tools, which were applied in
parallel as independent classiﬁcation (active/inactive) software. All
predictions of every program were summarized in a prediction
matrix (Table 4). After the biological testing, the hitlists were
analyzed and the performances of the applied tools were evaluated
and compared (Fig. 1).
2.2. Hardware speciﬁcation
All processes and predictions were performed on a multi-core
workstation with 2.4þ GHz, 8 GB of RAM, a 1þ TB fast mass stor-
age, and a NVIDIA graphical processing unit. All programs run on
theWindows 7 platform, except GOLD 5.0.1, which was installed on
openSUSE 12.2.
2.3. Screening database
The in-house database of the Institute of Pharmacy at the Uni-
versity of Innsbruck, Austria, was used for virtual screening. This
virtual database merges the chemical structures of compounds
synthesized at the Pharmaceutical Chemistry, isolated from plants
at the Pharmacognosy, stored at the Pharmaceutical Technology, or
used for student training in analytics. It contains already approved
drugs as well as published molecules with unknown biological
effects and completely new substances. In total, 2719 diverse
compounds are collected in the in-house database. The structures
of the compounds were manually assembled, therefore the data-
base did not undergo further treatment such as changes in the
protonation state.
Since every software program requires a different ﬁle format,
please refer to the respective method for a detailed description of
the database preparation.
2.4. Prospective screening methods
2.4.1. Pharmacophore modeling
The program LigandScout [13] version 3.02 was employed for
the generation of our internal pharmacophore models and the
prospective pharmacophore-based virtual screening. LigandScout
facilitates both structure- and ligand-based modeling: In a
structure-based approach, the experimentally determined inter-
action patterns are extracted from ligandetarget complexes such as
X-ray crystal structures. When using a ligand-based approach,
conformational models of known active ligands are aligned to
identify common electrochemical features. For further optimiza-
tion of initial pharmacophore models derived from both ap-
proaches, pharmacophore features can be manually added and
deleted, and their size and feature weight can be adapted. In
addition, optional features can be deﬁned. These features can, but
don't have to be mapped, however, if these features are matched
the score increases compared to compounds that don't ﬁt them. As
default, interaction patterns are represented by HBD, HBA, aromaticFig. 1. Study(Ar), positively (PI) and negatively (NI) ionizable, metal binding
(MB), and H features. Additionally, steric constraints can be
included in a model to mimic the binding pocket and prevent
mapping of compounds that would clash with the binding site.
Over the course of a virtual screening, LigandScout maps a pre-
calculated library of conformations to the pharmacophore model,
calculates how many features a database compound matches and
the overlap of the feature centers [33].
For a detailed description of the COX pharmacophore model
generation and validation, please refer toTemml et al. [26]. Multiple
COXeinhibitor complexes are available in the Protein Databank
(PDB) [32], therefore we exclusively employed structure-based
approaches for pharmacophore model generation. Initial pharma-
cophore models were automatically created for all complexes
deposited in the PDB [32] as described above. The models were
manually reﬁned with an active and decoy set, containing 100 and
99 active compounds for COX-1 and COX-2, respectively, and 4984
decoy molecules collected from the ChEMBL database [34]. The
smiles codes of these compounds are provided in the supporting
information. For the prospective screening, a maximum number of
100 conformers was calculated for every compound in the in-house
database using OMEGA [35e37] implemented in LigandScout [13].
We used models generated with LigandScout as described previ-
ously [26] for the prospective screening of the in-house database.
These models and their hitlists were then further analyzed.2.4.2. Shape-based modeling
ROCS [9,10] employs a Gaussian function to compare the shape
of a query molecule used for model building and the shapes of
screening compounds present in a database. The degree of
Gaussian function overlap is calculated as Shape Tanimoto score
[38], analogous to the Tanimoto coefﬁcient (Tc) used for 2D
similarity-based investigations, and it also ranks from zero to one.
ROCS also allows for the addition of so-called color features, which,
like pharmacophore features, represent electrochemical feature
types like HBD, HBA, anion (A), cation (C), ring (R), and H moieties.
Mapping of the database compounds to the color features is
measured with the ScaledColor score, where the individual ﬁt
values are normalized to the score of the query molecule (which
retrieves the maximum score). The ScaledColor score also ranks
from zero to one. Both ﬁt scores are combined in the ComboScore
via simple addition, thereby equally weighting both the shape
overlap and the mapping of the features. Consequently, the Com-
boScore ranks from zero to two.
Within this study, vROCS version 3.0.0 [9,10] was used. In total,
33 different shape-based models were generated using 23 different
PDB-entries. For the virtual screening, however, only two models
based on the crystal complexes of COX-1 and celecoxib (PDB-entry
3KK6 [39]) and methyl ester ﬂurbiprofen (PDB-entry 1HT5 [40])
were selected, because they performed best during the theoretical
validation.
For the theoretical validation of all ROCS-models, the data-sets
from the pharmacophore model generation were used, which are
brieﬂy described above [26]. Sincewe did not discriminate betweendesign.
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and 13 duplicate molecules were removed (the smiles codes of the
data-set compounds are provided in the supporting information).
The sd-ﬁles were converted to oeb.gz-ﬁles using the default set-
tings of OMEGA 2.3.2 [35e37], thereby generating a maximum
number of 200 conformers per molecule. For every structure in the
in-house database, one input conformation was calculated with
CORINA [41] and this database was again converted to an oeb.gz-
ﬁle with the default settings of OMEGA 2.3.2. Virtual screening
was performed with default settings and the results were ranked
according to the ComboScore.
2.4.3. Docking
The software program GOLD 5.0.1 [15,16] was used for the
molecular docking of compounds into the crystal structure of COX-
1 complexed with methyl ester ﬂurbiprofen (PDB entry 1HT5 [40]).
GOLD is based on a genetic algorithm, which mimics evolutionary
selection processes such as crossover and mutation. In this context,
the chromosomes represent possible ligand binding modes within
the binding pocket and consist of two binary and two integer
strings, where the binary strings encode the conformations of the
ligand and the protein, and the integer strings the formation of
hydrogen bonds of both the ligand and the protein and the ligand
with itself.
The ﬁtness function applied in this study, the GoldScore, is
composed of the hydrogen bond energy, the steric energy upon
binding of the ligand, and the internal energy of the ligand alone
[16].
For protein preparation, 9402 hydrogens were added, all waters
(150) were deleted, and the ligand was extracted. The area of 6 Å
surrounding the ligand was deﬁned as binding site. The docking
was performed in virtual screening mode and the GoldScore was
selected as Fitness function. The output was restricted to ten poses
per compound. For every structure in the in-house database, one
conformation was calculated with CORINA [41]. Only one crystal
structure of a COXeligand complex was employed for docking,
because it was reported in the literature that the binding site does
not undergo conformational changes upon binding of different
inhibitors [40].
2.5. Retrospective proﬁling tools
The 20 best-ranked hits of the pharmacophore-based, the
shape-based, and docking-based virtual screenings weremerged to
a combined hitlist, which was further investigated with external
pharmacophore- and 2D similarity-based proﬁling tools.
2.5.1. Pharmacophore-based methods
PharmaDB. Since version 3.5, Discovery Studio includes a
collection of 68,056 structure-based pharmacophore models for
2556 different targets [21]. They were automatically generated
from 7687 proteineligand complexes from the PDB, and subse-
quently selected based on a genetic function approximation (GFA)
model estimating the restrictivity of the pharmacophore models.
Every included model consists of three to six features. A maximum
number of 10 models was created for every complex. The models
were combined in a database called PharmaDB, which can be used
for compound proﬁling. The merged hitlist was screened by the
most selective pharmacophore model created with every
COXeligand complex. This subset of pharmacophore models is
provided in Discovery Studio and can be selected during setting up
a screening run. The selectivity of the models was determined by
using the same GFA model as described above [21].
PharmMapper. PharmMapper [6] is a freely accessible online
pharmacophore collection (http://59.78.96.61/PharmMapper/)intended for compound proﬁling. It consists of more than 7000
structure-based models for 1627 targets. The pharmacophore
models were automatically generated with LigandScout [13] and
then manually analyzed, however, a distinct algorithm is used for
virtual screening [6]. Every compound of the merged hitlist was
uploaded to the PharmMapper server separately and a maximum
number of 300 conformers was generated. All targets in the phar-
macophore collection were selected for proﬁling, however, the
output was limited to the 300 best-rankedmodels, and onlymodels
with at least six features were counted as hits.
2.5.2. 2D-similarity-based methods
SEA [19] (http://sea.bkslab.org/) and PASS [20] (http://www.
pharmaexpert.ru/passonline/) are 2D-similarity-based proﬁling
tools that are freely accessible online. SEA uses ECFP4 ﬁngerprints
to describe the 2D structure of compounds, and the similarity be-
tween single pairs of compounds is calculated as Tc. SEA employs a
statistical model to correct for “random similarity” to optimize the
results [19]. It is based on structures of ligands with annotated
biological activities from the ChEMBL Medicinal Chemistry Data-
base, the MDL Drug Data Report, theWorld of Molecular Bioactivity
(WOMBAT) database, and the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database to compare the structure and predict
the activity of querymolecules. The smiles code of every compound
from the merged hitlist served as input, and within this study the
ChEMBL version 10 and the WOMBAT database were selected for
proﬁling.
PASS relies on the same principle, but applies the Multilevel
Neighborhoods of Atoms (MNA) descriptor for representation. It
predicts the probability of a compound x to be active against target
y with an improved naïve Bayes algorithm. The online version
predicts over 3500 targets and biological activities, which were
collected manually from literature [20]. All molecules were uploa-
ded as mol-ﬁles.
2.6. Experimental testing
2.6.1. Materials
All compounds except fosfestrol were obtained from our in-
house library. A free sample of fosfestrol was a kindly provided
by Aronis (Moscow, Russia, http://www.aronis.ru/). Before biolog-
ical testing, the melting points (m. p.) of all compounds were
measured with a Koﬂer heating bench (Wagner & Munz, Type
WME) to conﬁrm their identity. The heating bench was “calibrated”
before use with benzil (m. p. of 95 C), acetanilide (m. p. 114.5 C),
phenacetin (m. p. 134.5 C), benzanilide (m. p. 163 C), salophen (m.
p. 191 C), dicyandiamide (m. p. 201 C), and saccharin (m. p.
228 C). In case the melting point differed from the literature data,
the compounds were additionally analyzed with 1H NMR or HPLC
mass spectrometry.
2.6.2. Biological testing
Selected compounds were tested for their COX-inhibiting ac-
tivity as described earlier [42]. All compounds and the positive
control (S)-ibuprofen (Sigma Aldrich) were dissolved in DMSO
(Sigma Aldrich) and tested in triplicates at a concentration of
20 mM. Brieﬂy, 5 ml of ram seminal vesicle COX-1 (1 U) (Sigma-
eAldrich) or human recombinant COX-2 (0.5 U) (SigmaeAldrich)
were added to 180 ml of cofactor mix containing 5 mM hematin
(SigmaeAldrich), 18 mM L-epinephrine (SigmaeAldrich), and
50 mM Na2EDTA (Roth) in 100 mM Tris-buffer (pH 8.0) (Biorad).
After addition of 10 ml test compound, (S)-ibuprofen, or DMSO, the
reaction mix was incubated for ﬁve minutes at room temperature.
The reaction was started by adding 5 ml of 10 mM arachidonic acid
(AA) (SigmaeAldrich) solved in ethanol. After incubation at 37 C
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the samples were diluted 1:15 in assay buffer. Prostaglandin E2
(PGE2) concentration was determined using the EIA Kit produced
by Enzo Life Sciences according to the manufacturer's protocol.
Absorbance was measured with a Tecan Inﬁnite M200 (Tecan
Group) plate reader at 405 nM. Results of test compounds and
positive control were calculated as % inhibition compared to un-
treated samples. IC50-values were measured for all compounds that
exhibited an inhibition of approx. 50% at 20 mM concentration. The
IC50 values were calculated as average of at least two independent
experiments performed at various concentrations and in triplicates.2.7. Analysis of the results
After the biological testing, the results were analyzed within
three categories. The ﬁrst category, early enrichment (EE), investi-
gated to which percentage the predicted activity of the top-20
ranked molecules could also be conﬁrmed in the biological assay.
EE¼

number of active compounds in the top 20 hitlist
number of all compounds in the top 20 hitlist

 100
(1)
The second category, overall enrichment (OE), analyzed if these
compounds were also predicted by the other methods above a
certain activity cut-off. The cut-offs were deﬁned either according
to the validation cut-off or to published data. For ROCS, a cut-off of a
ComboScore 1.00 was taken according to the theoretical valida-
tion cut-off, which is described later in more detail. For SEA, the
cut-off was set at an E-value4 as proposed by Lounkine et al. [5].
The cut-off was set at Pa 0.5 for PASS, because it was shown that
most active molecules are distributed above that threshold [43]. No
cut-off was used for the pharmacophore modeling approaches. The
cut-off for docking was determined as a GoldScore of 40.0 in the
theoretical validation.
OE ¼

number of active compounds
number of predicted compounds from the merged hitlist

 100
(2)
The last category investigated the predictive power of the
different tools and for this purpose, the numbers of true positive
(percentage of predicted and biologically active compounds, TP),
false positive (percentage of predicted but biologically inactive
compounds, FP), true negative (percentage of compounds that were
not predicted and indeed were biologically inactive, TN), and false
negative (percentage of compounds that were not predicted but
were biologically active, FN) hits, and the percentages of overall
true predictions (in the latter referred to as accuracy (Acc [44]))
were calculated. A prediction was considered as true, when a pre-
dicted molecule was active in the biological testing, but also, if it
was not predicted as a hit and inactive in the assay. The same cut-
offs as described above were applied.
Acc ¼

TP þ TN
TP þ TN þ FP þ FN

 100 (3)
To further analyze the composition of the top-20 hitlists, di-
versity metrics were calculated with Discovery Studio 3.5 [25].
AlogP, molecular weight, number of HBD and HBA, number of
rotatable bonds, number of rings in general and aromatic rings in
particular, and the molecular fractional polar surface area were
selected as parameters. For calculation of 2D structural similarity
distances, ECFP4 Fingerprints were used and the similarity wasdetermined with the Tc.
3. Results
3.1. Prospective screening methods
3.1.1. Pharmacophore modeling
The generation of the pharmacophore models was described
recently [26]. Brieﬂy, pharmacophore models were generated with
all suitable PDB entries available at that time, leading to 37 COX-1
and 27 COX-2 models. Many of these models mapped redundant
molecules from the test set, and therefore only a selection of the
best-performing, complementary models was applied for the pro-
spective part [26]. For the virtual screening of the in-house data-
base, the COX-1 models 1EQG (Fig. 2A), 1Q4G (Fig. 2B), 2AYL
(Fig. 2C), and the COX-2 models 3LN0 (Fig. 2D) and 3NTB (Fig. 2E)
were used. Those models were selected, because they retrieved the
compounds with the highest relative pharmacophore ﬁt value in
the course of the prospective screening. The three COX-1 models
were generated with the PDB entries 1EQG [40], 1Q4G [45], and
2AYL [46], in which COX-1 forms a complex with the inhibitors
ibuprofen, a-methyl-4-biphenylacetic acid, and ﬂurbiprofen,
respectively. The crystal structures of the two inhibitors SD-8381
(PDB entry 3LN0 [47]) and 6-methylthionaproxen (PDB entry
3NTB [48]) provided the basis for the two COX-2 pharmacophore
models, respectively. All hits derived from these models were
merged and ranked according to their relative geometric ﬁt values,
and the 20 best-ranked hits were selected for biological testing
(Table 1).
3.1.2. Shape-based modeling
Several different shape-based models were generated with
ROCS [9,10]. All the models generated in the course of this study
were based on co-crystallized COXeligands, because they represent
the bioactive conformations. The models were validated with the
same active and decoy set as was used for the pharmacophore
models. In total 33 different models covering 23 PDB-entries were
generated and two of them were ﬁnally selected for virtual
screening. Together, they scored 95% of the compounds from the
actives set, including both COX-1 and COX-2 active compounds,
with a ComboScore 1.0 and the AUCs in the ROC plots (for a
detailed description of ROC plots please refer to Triballeau et al.
[49]) were 0.71 and 0.70, respectively. These two models were
generated with the co-crystallized ligands of the PDB-entries 3KK6
[39] (celecoxib bound to COX-1, Fig. 3A) and 1HT5 [40] (methyl
ester ﬂurbiprofen bound to COX-1, Fig. 3B) using the default set-
tings. Although several steps were undertaken to improve the
automatically generated models manually, the unmodiﬁed ones
performed best. The two models were then used for virtual
screening the in-house database. The results were ranked accord-
ing to the ComboScore. The 20 highest scored hits were selected for
biological testing (Table 2).
3.1.3. Docking
For the docking, we aimed to use the X-ray crystal structures
used for shape-based modeling too. However, docking into the
PDB-entry 3KK6 [39] could not be successfully validated. Next, the
crystal structure of methyl ester ﬂurbiprofen bound to COX-1 was
evaluated for the docking studies (PDB-entry 1HT5 [40]). For vali-
dation of the docking workﬂow, the co-crystallized ligand was re-
docked into the binding site with an RMSD-value of 1.029 Å. In
addition, a subset of 50 active compounds and 60 decoys from the
test set was docked. The number of test set compounds was
restricted due to time-reasons; however, we focused on diverse
molecules. The diversity of the subset was analyzed with Discovery
Fig. 2. Pharmacophore models for COX-1 (AeC) and -2 (DeE). (A) The model 1EQG consists of three H features, three HBAs, one NI feature, and 27 XVOLs. (B) The model 1Q4G
contains three H features, of which the smallest one is optional, three HBAs, one NI feature, and 22 XVOLs. (C) In addition to 24 XVOLs, model 2AYL contains four H, four HBA, and
one NI feature. (D) The COX-2 model 3LN0 is composed of three H and three HBA features and 26 XVOLs. (E) The model 3NTB consists of 4 H features, of which the smallest one is
again optional, three HBAs, and 26 XVOLs.
Table 1
Top-20 ranked compounds from pharmacophoremodeling with descendent relative
ﬁt value.
Name Relative ﬁt value Model
Picosulfate sodium 0.9677 3LN0
(R)-ibuprofen 0.9634 1Q4G
mefenamic acid 0.9629 2AYL
Dienestrol diacetate (5) 0.9627 3LN0
Flunixin meglumine 0.9622 2AYL
p-kresalol (2) 0.9585 1Q4G
Tiaprofenic acid 0.9578 1EQG
Biﬂuranol (1) 0.9568 3LN0
Meclofenamic acid 0.9561 2AYL
(S)-ibuprofen 0.9557 1Q4G
Ketoprofen 0.9556 1EQG
Oxyphenisatin acetate 0.9548 3LN0
Dormin 0.9531 2AYL
Triﬂocin 0.9528 1EQG
Carprofen 0.9514 1Q4G
Alclofenac 0.9475 3LN0
3, 4-dichlorobenzoic acid 0.9459 3LN0
Cloﬁbric acid 0.9458 1Q4G
Pirprofen 0.9449 3LN0
Indometacin 0.9439 3LN0
Fig. 3. ROCS models generated with celecoxib (A) and methyl ester ﬂurbiprofen (B).
(A) In addition to the shape, the celecoxib comprised of three R features, three HBAs,
and one HBD feature. (B) The methyl ester ﬂurbiprofen model contained two R fea-
tures, one HBA feature, and one H feature.
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and the Tc. The active compounds and decoys retrieved an average
ﬁngerprint distance of 0.894 and 0.869, respectively. Based on the
docking run, we selected an activity cut-off of GoldScore 40.0,
because 41 of the 50 active compounds (82.0%), but only 15 of the
decoys (25.0%) were ranked above this threshold. This led to an AUC
of 0.76. In the prospective screening, the in-house database was
docked into the binding site. The results were ranked according to
the GoldScore, and the 20 best-ranked hits were selected for bio-
logical testing (Table 3). The highest ranked docking pose of the
top-20 ranked compound cyqualon (3) is depicted in Fig. 4.3.1.4. Investigation of the merged hitlist
All the compounds predicted with the three approaches
mentioned above were merged to one hitlist, which contained 52
molecules after the removal of 7 redundant compounds (pico-
sulfate was predicted by all three methods). Subsequently, the
hitlists of pharmacophore modeling, shape-based screening, and
docking were analyzed to investigate, whether some of the
remaining compounds of the merged hitlist were predicted above
the deﬁned cut-off, indicating consensus hits. After this merger,
pharmacophore modeling predicted 25 of the 52 compounds,
docking indicated 46 hits, and shape-based screening estimated all
52 compounds as active substances, respectively. In addition, all 52
compounds were proﬁled with the external pharmacophore-based
proﬁling tools PharmaDB and PharmMapper as well as with the 2D
Table 2
Top-20 hitlist from shape-based screening with descendent ComboScore.
Name ComboScore Model
Pirprofen 1.755 MFa
Indoprofen 1.673 MF
Tiaprofenic acid 1.658 MF
Carprofen 1.652 MF
Fenbufen 1.56 MF
Paxamate (4) 1.555 MF
Ketoprofen 1.532 MF
Dimetholizine 1.525 MF
(S)-ibuprofen 1.508 MF
Sulthiame 1.489 MF
17a-ethinylestradiol 1.485 MF
p-phenylacetanilide 1.481 MF
Norethynodrel 1.47 MF
Thiamine monochloride 1.468 MF
Sulfamidopyrin 1.467 MF
17a-ethinylestradiol-3-methylether 1.467 MF
(R)-ibuprofen 1.464 MF
Ticrynafen 1.447 MF
Picosulfate sodium 1.364 Cb
Triphenyltetrazol 1.349 C
a MF methyl ester ﬂurbiprofen model.
b C celecoxib model.
Table 3
Top-20 ranked compounds from docking with descendent GoldScore.
Name GoldScore
Sulfoxone 86.49
Picosulfate sodium 80.58
Azosemide 77.55
Acid orange 6 75.35
Chloramphenicol 74.42
Fosfestrol 72.38
Bisoprolol 72.33
Roniﬁbrate 69.80
Baludon 69.00
Ranitidine 68.80
Glafenine 68.25
Furosemid 68.20
Thyroxin 67.83
Benzothiazide 67.67
4-deoxypyridoxine-5-phosphate 67.21
Cyqualon (3) 67.02
Pitofenone 66.74
Sulfasalazin 66.59
Berberine 66.31
Flavoxate 66.10
Fig. 4. Highest scored docking pose of cyqualon (3) (dark gray) and the co-crystallized
ligand methyl ester ﬂurbiprofen (light gray).
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3.2. Retrospective proﬁling tools
3.2.1. Pharmacophore-based methods
PharmaDB. Only the 14 most selective models for COX with and
without shape included in the PharmaDB were selected for the
screening to minimize the screening time and avoid large data
volumes. 44 of the 52 molecules mapped at least one pharmaco-
phore model, and seven pharmacophore models were mapped in
total. The highest ﬁt values for all compounds that mapped at least
one model are listed in Table 4.
PharmMapper. The PharmMapper proﬁling predicted 11 com-
pounds to interact with either COX-1 or COX-2 within the top-300
ranked targets (Table 4).
3.2.2. 2D-similarity-based methods
SEA. In the course of the SEA proﬁling, 17 molecules were pre-
dicted with an E-value 4 and therefore considered as hits
(Table 4).
PASS. In the proﬁling with PASS, all results with a Pa-value  0.5
were considered as hits, in this case 24 out of 52 compounds
(Table 4).
3.3. Generation of a prediction matrix
The predictions generated with pharmacophore-based and
shape-based screening and molecular docking for the 52 unique
compounds from the merged hitlist were combined in a prediction
matrix. In parallel, the 52 compounds were investigated with the
bioactivity proﬁling tools SEA, PASS, PharmaDB, and PharmMapper,
and their predictions were added to thematrix. In case COX-activity
was reported, data from the literature was included as well. All
predictions are summarized in Table 4.
3.4. Preliminary analysis of the merged hitlist
For 14 of the proposed compounds, experimental data was
already available in the scientiﬁc literature. This was the case for
alclofenac [40], berberine [50], carprofen [51], (S)-ibuprofen [61],
fenbufen [52], ﬂunixin meglumine [53], (R)-ibuprofen [60], indo-
metacin [54], indoprofen [55], ketoprofen [56], meclofenamic acid
[57], mefenamic acid [58], pirprofen [59], and tiaprofenic acid [55].
All these compounds, except berberine were found to inhibit COX.
Berberinemodulates the AA cascade, and PGE2-levels are decreased
after berberine treatment, but this effect is regulated on the tran-
scriptional level, not by direct inhibition of the enzyme [50]. (R)-
ibuprofen was well accepted as the inactive stereoisomer of
racemic ibuprofen. However, Duggan et al. reported that (R)-
ibuprofen-mediated COX-inhibition is substrate-selective. While
PGE2 formation from AA is only inhibited at high concentrations,
the oxidation of endocannabinoids is prevented with an IC50 of
approximately 10 mM. The crystallization of other (R)-profens
revealed the same binding site and an analogous binding mode
compared to the (S)-enantiomers. Apparently, also (R)-profens bind
to the catalytic center of COX, and therefore (R)-ibuprofen was
considered as active [60]. Evidence for COX-inhibitionwas given for
sulfasalazin, however, no IC50 was available and the present data
suggest a very high value [62]. Unfortunately, the purity and
identity of sulfasalazin could not be conﬁrmed in our analyses,
thereby making it impossible for us to experimentally test this
compound. Due to the ambiguous data that exists, we could not
deﬁne the biological activity of sulfasalazine and excluded it from
the ﬁnal analysis list. In the case of cyqualon (3), COX-activity was
published by one group [63]. However, the investigation was only
Table 4
All predictions of pharmacophore modeling (PM), shape-based modeling (SHAPE), Docking (DOCK), SEA, PASS, PharmMapper, and the PharmaDB for the compounds in the
merged hitlist. Compounds ranked among the top-20 are highlighted in gray.
Compound name PMa SHAPEb DOCKc PharmaDBa PharmMappera SEAd PASSe Activity
17a-ethinylestradiol ef 1.49 e 0.91 e e e Inactive
17a-ethinylestradiol-3-methylether e 1.47 e 0.91 e e e Inactive
3,4-dichlorobenzoic acid 0.9459 1.04 e 0.22 0.4222 e 0.535 Inactive
4-deoxypyridoxine-5-phosphate 0.8286 1.09 67.21 0.78 e e e Identity not given
Acid orange 6 e 1.31 75.35 e e e e Inactive
Alclofenac 0.9475 1.32 53.92 0.81 0.5556 e 0.511 Active [40]
Azosemide e 1.24 77.55 0.69 e e 0.546 Inactive
Baludon e 1.20 69.00 e e e e Inactive
Benzothiazide e 1.15 67.67 0.60 e e 0.574 Inactive
Berberin e 1.33 66.31 0.55 0.5133 e e Inactive [50]
Biﬂuranol (1) 0.9568 1.08 e 0.43 0.5387 e 0.594 Active
Bisoprolol e 1.00 72.33 0.63 e e e Inactive
Carprofen 0.9514 1.65 62.66 0.84 0.4392 4.44E-12 0.882 Active [51]
Chloramphenicol e 1.12 74.42 e e e e Inactive
Cloﬁbric acid 0.9458 1.22 45.29 0.83 e 6.54E-19 0.635 Inactive
Cyqualon (3) e 1.04 67.02 0.73 0.4759 5.14E-04 0.63 Active
Dienestrol diacetate (5) 0.9627 1.16 58.40 0.13 e 6.06E-18 e Active
Dimetholizine e 1.53 53.68 0.86 e e e Inactive
Dormin 0.9531 1.05 41.34 0.81 e e e Not available
Fenbufen 0.8274 1.56 57.55 0.01 e e 0.57 Active [52]
Flavoxate e 1.10 66.10 0.03 e e e Identity not given
Flunixin meglumine 0.9622 1.11 47.85 0.69 0.61 e e Active [53]
Fosfestrol 0.9435 1.04 72.38 0.67 e e e Inactive
Furosemid e 1.28 68.20 0.44 0.50 e e Inactive
Glafenine e 1.02 68.25 0.70 e 2.61E-05 e Inactive
Indometacin 0.9439 1.35 57.47 0.72 0.65 1.80E-79 0.95 Active [54]
Indoprofen 0.9394 1.67 57.54 0.85 0.42 8.87E-13 0.65 Active [55]
Ketoprofen 0.9556 1.53 58.98 0.89 0.45 1.10E-31 0.90 Active [56]
Levothyroxin e 1.40 67.83 0.08 e e e Inactive
Meclofenamic acid 0.9561 1.08 52.10 0.76 0.48 1.89E-26 0.79 Active [57]
Mefenamic acid 0.9629 1.08 51.91 0.78 e 6.44E-25 0.60 Active [58]
p-phenylacetanilide e 1.48 46.83 e e e 0.60 Inactive
Norethynodrel e 1.47 e 0.76 e e e Inactive
Oxyphenisatin acetate 0.9548 1.17 e 0.00g e 3.06E-15 e Inactive
Paxamate (4) e 1.56 51.15 0.80 0.37 6.79E-18 0.53 Active
Picosulfate sodium 0.9677 1.36 80.58 0.74 e e e Inactive
Pirprofen 0.9449 1.76 57.77 0.86 e 1.97E-12 0.64 Active [59]
Pitofenone e 1.09 66.74 0.58 66.74 Inactive
p-kresalol (2) 0.9585 1.11 50.66 0.59 e 5.54E-18 e Active
Ranitidine e 1.02 68.80 0.86 0.54 e e Inactive
(R)-ibuprofen 0.9634 1.46 55.24 0.89 0.46 7.71E-15 0.88 Active [60]
Roniﬁbrate e 1.18 69.80 0.87 0.65 e 0.53 Inactive
(S)-ibuprofen 0.9557 1.51 56.26 0.89 e 7.71E-15 0.88 Active [61]
Sulfamidopyrine e 1.47 52.63 0.32 0.56 e e Not available
Sulfasalazin e 1.23 66.59 e e e 0.61 Identity not given
Sulfoxone e 1.00 86.49 e e e e Inactive
Sulthiame e 1.49 61.94 e e e 0.64 Inactive
Thiamine monochloride e 1.47 59.28 e 0.51 e e Inactive
Tiaprofenic acid 0.9578 1.66 58.91 0.84 e 2.17E-12 0.69 Active [55]
Ticrynafen 0.9391 1.45 56.34 0.82 e e 0.54 Inactive
Triﬂocin 0.9528 1.11 49.18 0.77 e 1.51E-11 e Identity not given
Triphenyltetrazol - 1.35 54.36 0.90 0.53 - 0.59 Inactive
The bestﬁt value is depicted in case more than one was obtained.
a Relative pharmacophore ﬁt value.
b The ComboScore was only reported above the deﬁned activity cut-off of 1.00.
c The GoldScore is only reported above the deﬁned activity cut-off of 40.00.
d The E-value is only reported below the deﬁned activity cut-off of 4.
e The Pa-value is only reported above the deﬁned activity cut-off of 0.5.
f The compound was either not predicted to be active by the respective method, or above (SEA)/below (all other methods) the deﬁned activity cut-off.
g Exact value 0.000213.
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et al. reported a study, where cyqualon (3) did not prevent PGE2-
formation in stimulated differentiated U937 cells [64]. To ﬁnally
determine the biological activity of cyqualon (3) and measure the
IC50 value, cyqualon (3) was included in the experimental testing.
The identity of 4-deoxypyridoxine-5-phosphate, ﬂavoxate hydro-
chloride, sulfasalazine, and triﬂocin could not be conﬁrmed by
melting point and NMR analyses, so they were excluded from
biological testing. Two further compounds, dormin andsulfamidopyrine, were not available anymore. Finally, 32 com-
pounds were subjected to experimental testing.3.5. Biological testing
In the biological assay, 5 of the 32 tested compoundswere active
with IC50 values between 2 and 38 mM. These compounds were
biﬂuranol (1), dienestrol diacetate (5), cyqualon (3), p-kresalol (2),
and paxamate (4). Interestingly, biﬂuranol (1), cyqualon (3), and
Table 5
IC50 values of the tested and active compounds.
Compound COX-1 (mM) COX-2 (mM)
Biﬂuranol (1) 33.0 ± 7.3 ea
Cyqualon (3) 1.5 ± 2.1 e
Dienestrol diacetate (5) 4.2 ± 1.5 2.0 ± 0.9
Paxamate (4) 17.1 ± 3.1 e
p-kresalol (2) 37.6 ± 6.8 18.2 ± 3.8
Ibuprofen (control) 3.3 ± 0.3 0.7 ± 0.4
a Inactive.
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and p-kresalol (2) inhibited both isoforms. This is surprising,
because biﬂuranol (1) and dienestrol diacetate (5) share the same
scaffold and differ only in the existence of the double-bonds and
the substitutions on the phenyl-moieties. COX-2 is assumed to have
a larger binding pocket, however, in this case the smaller com-
pound (biﬂuranol (1)) appears to be COX-1 selective, while the
larger one (dienestrol diacetate (5)) inhibits both. IC50 values and
chemical structures of all active compounds are displayed in Fig. 5
and Table 5, respectively. For a detailed list of the structures and
biological activities of the inactive compounds, please refer to the
supporting information.3.6. Evaluation of the prospective screening methods
3.6.1. Pharmacophore modeling
The application of our own pharmacophore models appeared to
be very successful in general and clearly outperformed the other
methods in the EE. From the top-ranked compounds 14 out of 18
predicted molecules (dormin was not available and the identity of
triﬂocin could not be conﬁrmed) were found to be active, leading to
an EE hit rate of 77.8%. The hit rate of OE was slightly lower and the
Acc even higher, with 72.7% and 82.6%, respectively. The overall
hitlist consisted of 34.8% TP, 47.8% TN, 13.0% FP, and 4.4% FN hits.
The EE hitlist of pharmacophore-based screening, if one considers
only the true actives, contained a lot of well-established COX-in-
hibitors (approximately 60% of the predicted compounds). This
seems problematic for a true prospective experiment, however, all
these compounds were not included in the test- and trainings set
andwere therefore considered “real” hits. The successful ﬁltering of
active compounds from the database showed the advantages of the
method and suggested the identiﬁcation of novel compounds in the
20 highest rankedmolecules also if another database was screened.
This is supported by the fact, that biﬂuranol (1), dienestrol diacetate
(5), and p-kresalol (2), were identiﬁed as novel COX-inhibitors.
These compounds were only found in the top-20 ranked mole-
cules in the hitlist of pharmacophore-based screening and would
not have been tested, if it this method had not been applied.Fig. 5. Structures and IC50 values of the active compounds.3.6.2. Shape-based modeling
Biological data for 19 of the top-20 ranked compounds were
available, because sulfamidopyrine was not available for testing
anymore. The activity of 9 of these 19 compounds could be
conﬁrmed, resulting in an EE hit rate of 47.4%. This is clearly better
that the performance in the OE and the Acc category, where the hit
rate was 39.1% in both categories. The Acc value was not higher,
because all compounds in the merged hitlist were predicted, and
therefore no TN, and consequently also 0.0% FN were found.
Approximately 61% of hits were FPs, and the remaining 39.1% were
TP hits. Similar to pharmacophore modeling, also the top-20 hitlist
of shape-based virtual screening contained a large amount of well-
known COX-inhibitors (approximately 40% of the predicted com-
pounds). In addition to the known ligands, the shape-based
screening allowed for the identiﬁcation of another new COX-
inhibitor, namely paxamate (4). This compound was only ranked
that high by shape-based screening and would have been missed, if
this method had not been applied. Shape-based virtual screening
yielded approximately 50% EE rate and, together with PharmaDB,
obtained the highest TP rate.
3.6.3. Docking
Docking clearly performed worst in EE, with only one active out
of 17 predicted compounds (the identity of 4-deoxypyridoxine-5-
phosphate, sulfasalazine, and ﬂavoxate hydrochloride could not
be conﬁrmed) and a hit rate of 5.9%. This is not surprising, since the
GoldScore was the only criteria for the selection of compounds. The
results were not inspected manually to avoid bias, and the limits of
scoring in docking are a well-known problem [12,65]. However,
docking performed surprisingly well in OE with 17 out of 40 pre-
dicted compounds being active and a hit rate of 42.5%. The per-
formance even improved when regarding the Acc. 22 of the 46
predictions were correct and lead to 47.8% of true predictions. This
formidable performance is, at least in parts, due to the narrow cut-
off used in the study, which improved the classiﬁcation of inactive
compounds. In detail, docking retrieved 10.9% TN, and only 2.2% FN
hits. The remaining hits were either correctly (37.0%) or incorrectly
(50.0%) classiﬁed as active. The new active compound in the top-20
hitlist of docking, cyqualon (3), is distinct from the common COX-
inhibitors considering its structure. It has to be highlighted, that
although the EE rate was not good, the new active compound
identiﬁed with docking represents a completely new scaffold. This
molecule was again only ranked so high by docking, and, similar to
the other methods, would have been missed if docking had not
been applied.
3.7. Evaluation of the retrospective proﬁling tools
3.7.1. Pharmacophore-based methods
For the two pharmacophore-based proﬁling tools PharmMapper
and PharmaDB, no data is available for the EE category. Every single
compound has to be proﬁled separately in PharmMapper, thereby
making it almost impossible to apply it for large databases. In
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maDB, but this is very time-consuming and produces a lot of data.
So we restricted our studies for all proﬁling tools to OE and Acc.
PharmaDB performed worse than PharmMapper, but still sur-
prisingly well if one considers that all the models were generated
using an automated protocol. In OE, 18 out of 39 (hit rate of 46.2%)
predicted compounds were active, and concerning Acc, 18 out of 46
(hit rate of 54.4%) predictions were true. In silico proﬁling with
PharmaDB retrieved 39.1% TP, 15.2% TN, 45.7% FP, and 0.0% FN hits.
PharmMapper The biological activity of 11 out of 19 compounds
predicted by PharmMapper could be conﬁrmed, leading to a hit rate
of 57.9% in OE. The performance in the Acc category was even
better, with 31 out of 46 predictions being true and a hit rate of
67.4%. In total, the hitlist of PharmMapper consisted of 23.9% TP,
43.5% TN, 17.4% FP, and 15.2% FN hits.
3.7.2. 2D-similarity-based methods
Analogous to PharmMapper, every compound has to be proﬁled
separately with SEA and PASS and therefore only the molecules of
the merged hitlist were investigated.
SEA outperformed all other methods in the OE category with 14
active compounds out of 17 predicted ones and a hit rate of 82.4%.
Also concerning Acc it performed very well (39 true predictions out
of 46, 84.8%). The hitlist of SEA comprised 30.4% TP, 54.4% TN, 6.5%
FP, and 8.7% FN hits.
PASS performed quite well, although worse than pharmaco-
phoremodeling and SEA, but clearly better than the other methods.
In OE, the biological activity of 15 out of 24 predicted compounds
could be conﬁrmed, thereby leading to a hit rate of 62.5%. The
performance improved in the Acc category, where 34 of the 46
predictions were correct (hit rate 74.8%). In total, PASS yielded
32.6% TP, 42.2% TN, 19.6% FP, and 6.5% FN hits. A detailed graphical
representation of all hitrates and calculated metrics is depicted in
Fig. 6.
4. Discussion
In general, all methods proved to be suitable for the retrospec-
tive and prospective identiﬁcation of COXeligands, and all perfor-
mances, except EE for docking, led to hit rates of nearly 40% and
more. However, we have to state that the database we used was
unintendedly biased. We selected a database that also containedFig. 6. Analyses of the performances. (A) hit rates in % for the categories EE, OE, and Acc. The
not used for prospective virtual screening. (B) Fractions of TP, FP, TN, and FN compounds in
screening; DOCK, docking.already approved drugs with the intention to, besides the identi-
ﬁcation of novel COX-inhibitors, also rationalize adverse events that
had been observed with the administration of a certain medication.
Since many anti-inﬂammatory drugs are already known, this led to
an enrichment of COX-inhibitors per se. However, none of these
compounds was included in the test- or trainings set for setting up
the models. Therefore, all of them can be counted as true hits.
The selection of the virtual screening method strongly depends
on the aim of a project and the available resources for biological
testing. For the identiﬁcation of structurally new and diverse li-
gands, docking seemed to be the most suitable method in our
study, although one has to accept a high FP rate, especially when
only the highest-ranked molecules are considered and without any
further ﬁltering of hits. To further investigate the question of hitlist
similarity and exploration of chemical space, the diversity metrics
of the top-20 ranked compounds for pharmacophore- and shape-
based modeling and docking were calculated with Discovery Stu-
dio. The values for ﬁngerprint distances ranged from zero to one,
meaning that for compounds with a value of zero there is no dis-
tance, e.g. compounds are identical from a 2D structural-point of
view. With increasing values compounds are becoming more dis-
similar. Interestingly, similar values were obtained for the average
ﬁngerprint distances for all threemethods. The values were 0.84 for
shape-based screening, 0.80 for pharmacophore modeling, and
0.88 for docking. A more detailed investigation of the ﬁngerprint
distances revealed that there were, however, differences in the
minimum and maximum ﬁngerprint distances observed, ranging
from 0.00 and 0.97 for shape-based screening to 0.00 and 0.93 for
pharmacophore modeling, and 0.62 and 0.97 for docking. Both
shape-based and pharmacophore-based screening hitlists retrieved
a minimum number of 0.00, because they ranked both (R)- and (S)-
ibuprofen very high. In contrast, the most similar compounds in the
docking hitlists retrieved a minimum distance of 0.62. The hitlists
also differed in the diversity of the ﬁngerprint features. This value is
deﬁned as the number of different features divided by the number
of molecules. Thereby high numbers reﬂect hitlists with a larger
variation of ﬁngerprint properties as hitlists with low numbers. The
values retrieved in this study ranged from 14.9 for pharmacophore
modeling to 16.55 and 23.25 for shape-based screening and dock-
ing, respectively. These results also emphasized the differences of
the methods in respect to hitlist diversity.
A high hit rate is much more important than hitlist diversityEE of the retrospective bioactivity proﬁling tools was not available, because they were
the hitlists of the respective tool. PM, pharmacophore modeling; SHAPE, shape-based
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effects or adverse events. Especially the number of FN hits should
be as low as possible to identify all potentially harmful compounds.
Different from a lead identiﬁcation project, the number of FP, in
contrast, can be larger in this setting. There were two tools, ROCS
and PharmaDB, which had high FP hit rates (60.9% and 45.7%,
respectively), but both also 0.0% FN hits. In addition, these two
programs yielded the highest TP rates (39.1% for both) of all applied
methods. Although ROCS predicted every compound in the merged
hitlist to be active and seemed to be totally unrestrictive, one has to
keep in mind that these compounds were already prioritized and
pre-selected by other methods, and don't represent a random se-
lection of molecules. Both programs, ROCS and PharmaDB, identi-
ﬁed all active compounds in the dataset, thereby making them
particularly useful for the prediction of COX-mediated side effects.
Recently, AbdulHameed et al. performed a retrospective multi-
target study, where they explored the suitability of ROCS for
target-ﬁshing, and for several compounds they successfully iden-
tiﬁed off-targets that had already been described in literature [4].
Also pharmacophore modeling and 2D-similarity based
methods turned out to be suitable for activity proﬁling. The TP hits
biﬂuranol (1) and dienestrol diacetate (5) share the same scaffold
and both belong to the class of selective estrogen receptor modu-
lators (SERMs). Their chemical structure is distinct from the com-
mon COX-inhibitors and this shows the applicability of
pharmacophore modeling also for scaffold hopping [66]. Another
member of this group, chlorotrianisene, was identiﬁed by SEA as
COX-inhibitor recently, thereby rationalizing the occurrence of
abdominal pain that was observed with chlorotrianisene treatment
[5]. These examples again highlight the ability of in silico tools to
elucidate and predict adverse events. SEA and PASS emerged also as
powerful tools, because the investigation of a single compound of
interest is extremely fast and easy to handle. On the other side, the
non-commercial versions have the disadvantage that only one
molecule after the other can be analyzed, which makes the
screening of large databases rather difﬁcult. PharmaDB is in prin-
ciple intended for proﬁling of whole databases. To investigate the
utility of this tool for the generation of a bioactivity spectrum, we
performed a proﬁling run with cyqualon (3). Although we only
applied the most selective models without shape (7303 models in
total), we obtained 457 matching pharmacophores, which repre-
sent 6.3% of the database. So despite only screening with a small
part of the overall pharmacophore model collection, we got a quite
large number of hits. Therefore, the applicability of this tool may be
limited by the (unrealistically) large amount of data. We assume
that this can in part be attributed to the fact that the composition of
the models was restricted to six features, thereby making even the
more selective models rather unselective.
The comparison of the three different pharmacophore tools
pointed out the importance and the impact of careful model gen-
eration and validation. Our own pharmacophore models, which
were generated and validated manually, performed clearly better
than PharmMapper and PharmaDB, where models were generated
automatically (OE and Acc of 72.7% and 82.6% for our own models
versus 57.9% and 67.4% for PharmMapper and 46.2% and 54.4% for
PharmaDB), respectively. Also PharmMapper, where the automat-
ically generated models were subsequently manually analyzed [6],
performed better than the PharmaDB.
In a recent study, Venkatraman et al. compared the performance
of different shape-based and 2D ﬁngerprint ebased screening tools
using 40 targets of the Directory of Useful Decoys (DUD) [67]
dataset, including COX-1 and -2. Similar to our results, they
observed a better performance of the 2D-similarity tools, which
they attributed to the limitation of 3D shape-based methods to
cover the bioactive conformation of query and database molecules[31]. However, this may only partly apply for this study since we
used co-crystallized ligands for model generation, which are most
likely represented in their bioactive conformation, or a very similar
one, in the crystal. Krüger and Evers also compared the perfor-
mances of different in silico methods for the identiﬁcation of COX-
inhibitors, and in this study ROCS performed best of all methods
[30]. Unfortunately, they limited their analysis to ROCS, docking,
Scitegic Functional Fingerprints, and Feature Trees, and did not
include pharmacophore modeling. ROCS and docking performed
almost similar in their study, and we also observed no big differ-
ences in the performances of these two approaches regarding OE
and Acc. In contrast, their 2D-similarity search was clearly out-
performed by ROCS and docking. This may be due to the fact, that
they used another descriptor (Functional-Class Fingerprints 4,
FCFP4) than the ones applied in PASS (MNA) and SEA (ECFP4). In
addition, they only used one ligand as a reference molecule, while
PASS had a set of 1376 actives for COX-1, 3370 actives for COX-2, and
4216 actives for COX in general. SEA used 119 active compounds for
sheep, 27 for mouse, 135 for rat, and 499 for human COX-1, and
1875 active compounds for human, 151 for rat, 186 for sheep, and
253 for mouse COX-2 in the ChEMBL10. These large data volumes
allow for covering a much bigger chemical space for one target and
may contribute to the excellent performance we observed. Krüger
and Evers also noticed, that despite overlapping results, the hitlists
of the distinct methods are highly complementary and that every
method contributed on its own to identifying active molecules.
Considering hitlist complementarity, seven overlapping hits have
been obtained in our study in the top-20 hitlists of all three
methods. Six of these redundant hits were already known COX-
inhibitors, and the one with unknown biological activity, pico-
sulfate sodium, was inactive. Intriguingly, picosulfate sodium was
the only compound that was ranked among the top-20 hits by all
three methods. All of the six known COX-inhibitors were predicted
by both pharmacophore modeling and shape-based screening. In
contrast, all of the newly identiﬁed COX-inhibitors have only been
ranked in the top-20 of onemethod (a comprehensive discussion of
these novel COX-inhibitors is provided in the supporting informa-
tion). In detail, this comprises paxamate (4) identiﬁed with shape-
based screening, biﬂuranol (1), dienestrol diacetate (5), and p-
kresalol (2) proposed by pharmacophore modeling, and cyqualon
(3) suggested by docking. These results also demonstrate that,
similar to the study of Krüger and Evers [30], every method on its
own contributed to the identiﬁcation of new COX-inhibitors.
Recent trends in computer-aided drug design also force the
combination of methods for drug identiﬁcation to increase
enrichment rates [68]. In order to investigate the inﬂuence of
consensus scoring on the hit rates, we calculated the percentage of
biologically active and inactive compounds that have been pre-
dicted by increasing numbers of tools, and plotted it according to
the biological activity (Fig. 7). For example 100% of compounds that
have been predicted by all seven tools were active, while 100% of
compounds that were predicted solely by two tools were inactive.
Since no compoundwas predicted only by onemethod, we selected
a range of two to seven tools. We performed regression analysis and
observed a signiﬁcant correlation between the bioactivity and the
number of tools that predicted a compound (for both active and
inactive compounds R2 ¼ 0.88, and p ¼ 0.0059). Therefore, the
more tools predicted a compound to be active, the more likely it
was active in the biological assay and vice versa.
In conclusion, all applied methods performed intriguingly well.
We are aware of the fact that this single prospective study doesn't
allow for a general conclusion concerning the applicability of the
describedmethods, especially as we assume that different methods
might be differently suitable for different targets. Also Sastry et al.
have observed variances in the performance of methods depending
Fig. 7. Regression analysis of consensus hits reveals a strong correlation between the
biological activity and the number of predictions (R2 ¼ 0.88, p ¼ 0.0059). The per-
centage of active/inactive compounds in the consensus hitlist were plotted against the
number of tools that predicted a compound.
T. Kaserer et al. / European Journal of Medicinal Chemistry 96 (2015) 445e457456on the target [68], and further investigations on multiple targets
will be required to optimize the application of the various in silico
tools. However, even in the limited scope of this study, we observed
substantial differences not only in the hit rates, but also in the
composition of the hitlists. Our analysis highlights the advantage of
consensus methods in identifying active compounds. It is well
accepted that the combination of multiple protein structures and
scoring functions improves the results of docking [69,70]. Also for
ligand-basedmethods, where consensus scoring is often referred to
as data fusion, this has been proven [71,72]. However, for combi-
nations of multiple different methods as applied here, only few
studies have been published [68,73]. All studies reported in this
context were conducted in a retrospective manner and to the best
of our knowledge, our study is the ﬁrst one showing that this also
applies for prospective experiments. However, one has to be aware
that a consensus approach also always represents a restriction of
the original hitlist. Since every method contributed on its own to
the identiﬁcation of novel active molecules, the risk of missing
actually active compounds rises when a consensus approach is
applied. This may be of subordinate importance in a lead identiﬁ-
cation project, but during a screening for adverse events, it might
be relevant.
The suitability of the tools may largely depend on various pa-
rameters like the available data, the properties of the target/ligands,
the ﬁeld of application, and many more, and therefore, one should
carefully select the method of choice according to the project
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